This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gottesman, M H Articles by Friedman-Urevich, S Search for Related Content PubMed PubMed Citation Articles by Gottesman, M H Articles by Friedman-Urevich, S Social Bookmarking                   What's this?

Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS)

Winthrop University Hospital, Old Country Road, Mineola, NY 11501, USA, mgottesm{at}winthrop.org

S Friedman-Urevich

Winthrop University Hospital, Old Country Road, Mineola, NY 11501, USA

The approved interferon beta-1b (Betaseron®/Betaferon®) dose is 250 mg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data suggest a dose-response effect for interferon beta in multiple sclerosis (MS) treatment and a maximum dose has yet to be established. The Interferon Dose Escalation Assessment of Safety (IDEAS) study evaluated the safety and tolerability of interferon beta-1b 500 mg (16 MIU) sc eod with structured dose escalation and adverse event (AE) management in 22 patients (20 interferon beta-1b-treated (SD) and two interferon beta-1b-naïve (ND)) with relapsing-remitting (RR) MS, secondary-progressive (SP) MS, or progressive relapsing MS. IDEAS comprised an eight-week dose escalation period and a 12-week maintenance period, with modification as clinically warranted. Autoinjectors were used for all injections 0.4 mL. Clinical laboratory values were monitored monthly. Baseline and exit assessments included the MS Functional Composite score, EDSS, and neutralizing antibody MxA assay. AEs were recorded at every injection. Dose escalation ranged from two to 12 weeks. Some 91% of patients (20/22) achieved the 500-mg dose, and of these 90% (18/20) completed the maintenance phase. There were no differences in response between ND and SD patients. Most common AEs were decreased general well-being, insomnia, and injection site reactions (mostly mild). The 500-mg dose of interferon beta-1b was well tolerated in the short-term with escalation and premedication in these patients, most of whom had previously been receiving 250 mg interferon beta-1b.

Key Words: adverse events • clinical trial • dose escalation • interferon beta • multiple sclerosis • therapy

Multiple Sclerosis, Vol. 12, No. 3, 271-280 (2006)
DOI: 10.1191/135248506ms1261oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?